EUVIMEDPoznaj EUVIMED
Open access · CC BY 4.0

Plasma phosphorylated-tau217 is increased in Niemann–Pick disease type C

Fernando Gonzalez-Ortiz iD, Thomas K Karikari iD, Danielle Taylor-Te Vruchte, Dawn Shepherd, Bjørn-Eivind Kirsebom iD, Tormod Fladby, Frances Platt iD, Kaj Blennow

Brain Communications · 2024-10-30 · 6 (6)

DOI: 10.1093/braincomms/fcae375 ↗

At a glance

Journal article in Brain Communications, published online on 2024-10-25. Written by Fernando Gonzalez-Ortiz and 7 co-authors. Institution: Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölnd…. Cited 17 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY 4.0). Funded by: NIA NIH HHS, Anna Lisa and Brother Björnsson’s Foundation, Emil och Maria Palms Foundation.

AbstraktSubjectsDane bibliograficzneCiteRelated studies

Abstract (original language)

Niemann–Pick disease type C and Alzheimer’s disease are distinct neurodegenerative disorders that share the presence of neurofibrillary tangle pathology. In this multicentre study, we measured plasma phosphorylated-tau217 in controls (n = 60), Niemann–Pick disease type C (n = 71) and Alzheimer’s disease (n = 30 positive for amyloid and negative for tau in CSF [A+T−] and n = 30 positive for both [A+T+]). Annual Severity Increment Score and Lysotracker measurements were evaluated in the Niemann–Pick disease type C group to estimate the rate of progression and lysosomal enlargement, respectively. In the cross-sectional analysis, plasma phosphorylated-tau217 was increased in Niemann–Pick disease type C compared with controls (2.52 ± 1.93 versus 1.02 ± 0.34 pg/mL, respectively, P < 0.001) and inversely correlated with age at disease onset (R = −0.54, P < 0.001). In the longitudinal analysis, plasma phosphorylated-tau217 was associated with disease progression determined by Annual Severity Increment Score (R = 0.48, P < 0.001) and lysosomal enlargement (R = 0.26, P = 0.004). We found no differences between A+T− Alzheimer’s disease and Niemann–Pick disease type C (2.67 ± 1.18 versus 2.52 ± 1. 93 pg/mL, P = 0.31); however, A+T+ Alzheimer’s disease had significantly higher levels than Niemann–Pick disease type C (3.26 ± 1.36 versus 2.52 ± 1.93 pg/mL, P = 0.001). Our findings suggest that plasma p-tau217 can increase in brain disorders with isolated tau pathology. Plasma p-tau217 associations with disease progression and severity make it a potential marker in Niemann–Pick disease type C.

Subjects

Author keywords

blood biomarkersdementialysosomal dysfunctionneurodegenerationtau pathology

Authors and institutions

  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, 43180, Sweden.
  • Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, 43180, Sweden.
  • Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15203, USA.
  • Department of Pharmacology, University of Oxford, Oxford OX1 3QT, UK.
  • Department of Neurology, University Hospital of North Norway, Tromsø, 9019, Norway.
  • Department of Psychology, Faculty of Health Sciences, The Arctic University of Norway, Tromsø, 9031, Norway.

ORCID profiles: Fernando Gonzalez-Ortiz, Thomas K Karikari, Bjørn-Eivind Kirsebom, Frances Platt

Funding

  • NIA NIH HHS
  • Anna Lisa and Brother Björnsson’s Foundation
  • Emil och Maria Palms Foundation
  • Swedish Research Council
  • Swedish Alzheimer Foundation
  • Hjärnfonden, Sweden
  • Avtal om Läkarutbildning och Forskning
  • Alzheimer's Association

Cite

APA

Gonzalez-Ortiz, F., Karikari, T. K., Taylor-Te Vruchte, D., Shepherd, D., Kirsebom, B. E., Fladby, T., Platt, F., & Blennow, K. (2024). Plasma phosphorylated-tau217 is increased in Niemann–Pick disease type C. Brain Communications, 6(6). https://doi.org/10.1093/braincomms/fcae375

Vancouver

Gonzalez-Ortiz F, Karikari TK, Taylor-Te Vruchte D, Shepherd D, Kirsebom BE, Fladby T, et al. Plasma phosphorylated-tau217 is increased in Niemann–Pick disease type C. Brain Communications. 2024;6(6). doi:10.1093/braincomms/fcae375

BibTeX
@article{GonzalezOrtiz2024,
  author = {Gonzalez-Ortiz, Fernando and Karikari, Thomas K and Taylor-Te Vruchte, Danielle and Shepherd, Dawn and Kirsebom, Bjørn-Eivind and Fladby, Tormod and Platt, Frances and Blennow, Kaj},
  title = {Plasma phosphorylated-tau217 is increased in Niemann–Pick disease type C},
  journal = {Brain Communications},
  year = {2024},
  volume = {6},
  number = {6},
  doi = {10.1093/braincomms/fcae375}
}
Start for free →